Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib in Relapsed/Refractory Classical Hodgkin's Lymphoma
NCT02824029Phase 2Completed
- Sponsor
- Barbara Ann Karmanos Cancer Institute
- Start
- Jun 2016
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ibrutinib in classical Hodgkin lymphoma (cHL), sponsored by Barbara Ann Karmanos Cancer Institute. Started Jun 2016; status: completed.
02
Drugs
ibrutinib
03
Conditions
classical Hodgkin lymphoma (cHL)
Beyond the preview
Go deeper on NCT02824029.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02824029.